Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • Praxis Precision Medicines' Change in Account Payables fell 7163.86% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 10021.53%. This contributed to the annual value of $6.7 million for FY2024, which is 17581.03% up from last year.
  • Latest data reveals that Praxis Precision Medicines reported Change in Account Payables of $2.0 million as of Q3 2025, which was down 7163.86% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Change in Account Payables registered a high of $10.4 million during Q1 2025, and its lowest value of -$9.0 million during Q2 2023.
  • Moreover, its 4-year median value for Change in Account Payables was $2.0 million (2025), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' Change in Account Payables tumbled by 51988.95% in 2023, and later soared by 88366.89% in 2024.
  • Quarter analysis of 4 years shows Praxis Precision Medicines' Change in Account Payables stood at $4.6 million in 2022, then crashed by 128.55% to -$1.3 million in 2023, then plummeted by 91.07% to -$2.5 million in 2024, then skyrocketed by 180.06% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $5.9 million for Q2 2025, and $10.4 million during Q1 2025.